Evidence map›Paper›PMID 41730663›Full record

ArticleEndocrine journal2026

Impacts of the use of chemiluminescent enzyme immunoassay-measured plasma aldosterone concentration in the diagnostic process of unilateral primary aldosteronism: a real-world multicenter study in Japan.

Shoichiro Izawa, Kazuhisa Matsumoto, Kanako Kadowaki, Toshifumi Nakamura, Norio Wada, Takuyuki Katabami, Yoichi Nozato, Ryuji Okamoto, Takamasa Ichijo, Daisuke Taura and 12 more

Abstract readMulticenter Study
In one paragraph

Article in Endocrine journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Shoichiro IzawaDivision of Endocrinology and Metabolism, Tottori University Faculty of Medicine, Yonago 683-8504, Japan.ORCID http://orcid.org/0000-0003-2571-2875
Kazuhisa MatsumotoDivision of Endocrinology and Metabolism, Tottori University Faculty of Medicine, Yonago 683-8504, Japan.ORCID http://orcid.org/0000-0002-1566-7321
Kanako KadowakiDivision of Endocrinology and Metabolism, Tottori University Faculty of Medicine, Yonago 683-8504, Japan.ORCID http://orcid.org/0009-0006-1328-6951
Toshifumi NakamuraDivision of Endocrinology, Metabolism, and Nephrology, Department of Internal Medicine, Keio University School of Medicine, Tokyo 160-8582, Japan.ORCID http://orcid.org/0000-0003-2485-7028
Norio WadaDepartment of Diabetes and Endocrinology, Sapporo City General Hospital, Sapporo 060-8604, Japan.ORCID http://orcid.org/0000-0001-9796-4890
Takuyuki KatabamiDepartment of Metabolism and Endocrinology, St. Marianna University Yokohama City Seibu Hospital, Yokohama 241-0811, Japan.ORCID http://orcid.org/0000-0002-0396-8645
Yoichi NozatoDepartment of Geriatric and General Medicine, The University of Osaka Graduate School of Medicine, Suita 565-0871, Japan.ORCID http://orcid.org/0009-0003-4077-094X
Ryuji OkamotoDepartment of Cardiology and Nephrology, Mie University Graduate School of Medicine, Tsu 514-8507, Japan.ORCID http://orcid.org/0000-0002-8067-398X
Takamasa IchijoDepartment of Diabetes and Endocrinology, Saiseikai Yokohamashi Tobu Hospital, Yokohama 230-8765, Japan.ORCID http://orcid.org/0000-0002-2969-7396
Daisuke TauraDepartment of Diabetes, Endocrinology and Nutrition, Kyoto University Graduate School of Medicine, Kyoto 606-8507, Japan.ORCID http://orcid.org/0000-0002-4330-2370
Masanori MurakamiDepartment of Molecular Endocrinology and Metabolism, Graduate School of Medical and Dental Sciences, Institute of Science Tokyo, Tokyo 113-8519, Japan.ORCID http://orcid.org/0000-0002-5541-3502
Miki KakutaniDepartment of Diabetes, Endocrinology and Clinical Immunology, School of Medicine, Hyogo Medical University, Nishinomiya 663-8501, Japan.ORCID http://orcid.org/0000-0002-7112-1585
Takashi YonedaDepartment of Health Promotion and Medicine of the Future, Graduate School of Medical Science, Kanazawa University, Kanazawa 920-8640, Japan.ORCID http://orcid.org/0000-0002-0921-158X
Minemori WatanabeDepartment of Endocrinology and Diabetes, Okazaki City Hospital, Okazaki 444-8553, Japan.ORCID http://orcid.org/0009-0007-2956-8539
Yutaka TakahashiDepartment of Diabetes and Endocrinology, Nara Medical University, Kashihara 634-8522, Japan.ORCID http://orcid.org/0000-0002-1337-9246
Shintaro OkamuraDepartment of Endocrinology, Tenri Hospital, Tenri 632-8552, Japan.ORCID http://orcid.org/0000-0002-1205-6883
Katsutoshi TakahashiDivision of Metabolism, Showa General Hospital, Kodaira 187-8510, Japan.ORCID http://orcid.org/0000-0002-4804-1771
Hiroki KobayashiDivision of Nephrology, Hypertension, and Endocrinology, Department of Internal Medicine, Nihon University School of Medicine, Tokyo 173-8610, Japan.ORCID http://orcid.org/0000-0002-9674-0374
Mitsuhide NaruseEndocrine Center, Ijinkai Takeda General Hospital, Kyoto 601-1495, Japan.ORCID http://orcid.org/0000-0002-8977-4090
Kenichi YokotaDivision of Metabolism and Endocrinology, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki 216-8511, Japan.ORCID http://orcid.org/0000-0001-9648-182X
Masakatsu SoneDivision of Metabolism and Endocrinology, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki 216-8511, Japan.ORCID http://orcid.org/0000-0002-0757-7529
JPAS-II Study Group

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Unilateral primary aldosteronism (UPA) is characterized by a severe clinical phenotype and can be cured by adrenalectomy. Establishing accurate cutoff values that indicate the need for adrenal venous sampling (AVS) is crucial. Therefore, we aimed to identify appropriate cutoff values for screening and confirmatory testing to predict UPA by LC-MS/MS-equivalent plasma aldosterone concentration (PAC) using chemiluminescent enzyme immunoassay (CLEIA). A retrospective cohort analysis was conducted as part of the JPAS-II study of 443 patients diagnosed with PA using CLEIA-measured PAC, of whom 179 were confirmed by AVS as having UPA. The screening aldosterone-to-renin ratio (sARR), screening PAC, post-captopril challenge test (CCT) aldosterone-to-renin ratio (ARR), post-CCT PAC, and post-saline infusion test (SIT) PAC were significantly higher in patients with UPA than in those with bilateral PA (p < 0.05). Receiver operator characteristic curve analysis yielded an sARR cutoff value of >183 pg/mL/ng/mL/h (sensitivity of 0.95). The post-CCT ARR (AUC: 0.824 ± 0.022) and post-CCT PAC (AUC: 0.845 ± 0.021) were superior predictors of UPA to post-SIT PAC (AUC: 0.782 ± 0.037). When the cutoff values were designed to maximize sensitivity without a significant reduction in specificity, cutoff values for post-CCT ARR of >153 pg/mL/ng/mL/h (sensitivity: 0.85, specificity: 0.55) and for post-SIT PAC of >48 pg/mL (sensitivity: 0.80, specificity: 0.61) were obtained. Importantly, these cutoff values contributed to a diagnosis of UPA when the presence of hypokalemia or adrenal tumor was also considered. In conclusion, LC-MS/MS-equivalent CLEIA-measured cutoff values for post-CCT ARR of >153 pg/mL/ng/mL/h and for post-SIT PAC of >48 pg/mL are considered to indicate AVS. Study registration number: UMIN ID: 000046631.

Indexed as

AldosteroneHyperaldosteronismAdultAgedFemaleHumansImmunoenzyme TechniquesJapanLuminescent MeasurementsMaleMiddle AgedReninRetrospective StudiesSensitivity and SpecificityAldosteroneReninChemiluminescent enzyme immunoassayPlasma aldosterone concentrationPlasma renin activityPrimary aldosteronismRadioimmunoassay

Identifiers

PMID41730663
PMCPMC13271860

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.